GLPwatch
In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide.
Ann Intern Med · 2021
Last updated 2026-05-28In a study of 1,879 adults with type 2 diabetes, tirzepatide reduced blood sugar control (measured by HbA1c) more than semaglutide over 40 weeks. Participants received either 5 mg, 10 mg, or 15 mg of tirzepatide or 1 mg of semaglutide.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2021 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Frias JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385:503-15. 34170647.
Verbatim abstract via PubMed 34724396 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.